Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
Impel NeuroPharma (NASDAQ: IMPL) announced that Adrian Adams, Chairman and CEO, will present a company overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 1:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel NeuroPharma (NASDAQ: IMPL) announced that Adrian Adams, Chairman and CEO, will present a company overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 1:30 p.m. ET. The presentation will focus on transformative therapies for central nervous system diseases, highlighting Impel's Precision Olfactory Delivery technology and its approved product Trudhesa for migraine treatment. A live webcast will be available on their website, with a replay offered for 90 days.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was +0.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.
A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.